Oragenics Inc. (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion) are now active and enrolling participants. The activation of Royal Adelaide Hospital completes the site activation process, and the company reported that no serious adverse events have been observed in dosed participants to date. Oragenics continues to target a Phase IIa data readout in the fourth quarter of 2026.
In parallel, Oragenics submitted a Type B meeting request to the U.S. Food and Drug Administration on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company noted that this meeting supports its goal of submitting an Investigational New Drug application in the fourth quarter of 2026. ONP-002 is delivered via Oragenics' proprietary intranasal delivery technology, which is designed to rapidly transport therapeutics to the brain, bypassing the blood-brain barrier.
Mild traumatic brain injury, commonly known as concussion, represents a significant unmet medical need with no approved pharmacological treatments currently available. Oragenics is positioning ONP-002 as a potential first-in-class therapy that could address the acute phase of concussion, aiming to reduce neurological damage and improve recovery outcomes. The Australian trial is a critical step in generating safety and efficacy data to support global development.
The company's intranasal delivery platform has potential applications beyond concussion, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders, as outlined on their website at oragenics.com. The successful activation of all Australian sites and the absence of serious adverse events are positive indicators as Oragenics advances its clinical program. Investors can follow updates via the company's newsroom at https://ibn.fm/OGEN.
The announcement underscores Oragenics' commitment to developing innovative therapies for neurological conditions with high unmet needs. The upcoming FDA meeting and planned IND submission in late 2026 will be pivotal milestones for the program. For more details on the press release, visit https://ibn.fm/Yye2E.
